



HAL
open science

Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats

Andrea Bari, David Edward Harry Theobald, Daniele Caprioli, Adam C Mar, Alex Aidoo-Micah, Jeffrey W. Dalley, Trevor W Robbins

► To cite this version:

Andrea Bari, David Edward Harry Theobald, Daniele Caprioli, Adam C Mar, Alex Aidoo-Micah, et al.. Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. *Neuropsychopharmacology*, 2010, n/a (n/a), pp.n/a-n/a. 10.1038/npp.2009.233 . hal-00506037

HAL Id: hal-00506037

<https://hal.science/hal-00506037>

Submitted on 27 Jul 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats

Bari A ^{1,3}, Theobald DE ¹, Caprioli D ¹, Mar AC ¹, Aidoo-Micah A ¹, Dalley JW ^{1,2},
Robbins TW ¹

¹Behavioral and Clinical Neuroscience Institute and Department of Experimental Psychology, University of Cambridge, Cambridge CB2 3EB, UK. ²Department of Psychiatry, Addembroke's Hospital, University of Cambridge, Cambridge CB2 2QQ, UK.

³Corresponding author:

Andrea Bari

Department of Experimental Psychology

University of Cambridge

Downing Street, CB2 3EB

Cambridge, UK

Tel: +44 01223 339564

Fax: +44 01223 333564

Email: ab658@cam.ac.uk

Abstract

Depressed patients show cognitive deficits that may depend on an abnormal reaction to positive and negative feedback. The precise neurochemical mechanisms responsible for such cognitive abnormalities have not yet been clearly characterized, although serotonergic dysfunction is frequently associated with depression. In three experiments described here, we investigated the effects of different manipulations of central serotonin (5-HT) levels in rats performing a probabilistic reversal learning task which measures response to feedback. Increasing or decreasing 5-HT tone differentially affected behavioral indices of cognitive flexibility (reversals completed), reward sensitivity (win-stay) and reaction to negative feedback (lose-shift). A single low dose of the selective serotonin reuptake inhibitor (SSRI) citalopram (1 mg/kg) resulted in fewer reversals completed and increased lose-shift behavior. By contrast, a single higher dose of citalopram (10 mg/kg) exerted the opposite effect on both measures. Repeated (5 mg/kg, daily, seven days) and sub-chronic (10 mg/kg, i.b.d., five days) administration of citalopram increased the number of reversals completed by the animals and increased the frequency of win-stay behavior, while global 5-HT depletion had the opposite effect on both indices. These results show that boosting 5-HT neurotransmission decreases negative feedback sensitivity and increases reward (positive feedback) sensitivity, while reducing it has the opposite effect. However, these effects depend on the nature of the manipulation used: acute manipulations of the 5-HT system modulate negative feedback sensitivity, while long-lasting treatments specifically affect reward sensitivity. The results parallel some of the findings in humans on effects of 5-HT manipulations and are relevant to hypotheses of altered response to feedback in depression.

Keywords: serotonin, citalopram, probabilistic reversal learning, 5-HT depletion, negative feedback sensitivity, reward sensitivity

Introduction

Abnormal reactions to positive or negative events are associated with pathological states such as anxiety and depression (Beats *et al*, 1996; Elliott *et al*, 2000; Elliott *et al*, 1997; Graeff *et al*, 1996; Murphy *et al*, 2003). Such behavioral aberrations, for example, are common in depressive states in which patients' reactions to negative feedback are often exaggerated, while positive events fail to adequately reinforce behavior (Beats *et al*, 1996; Elliott *et al*, 1996; Henriques *et al*, 1994; Hughes *et al*, 1985; Murphy *et al*, 2003; Robbins *et al*, 1996; Steffens *et al*, 2001). The abnormal response to negative feedback displayed by depressive patients can be seen as part of a larger motivational deficit and is considered to be an important link between emotional and cognitive disturbances in depression (Elliott *et al*, 1997).

Serotonin (5-hydroxytryptamine; 5-HT) has long been implicated in the pathophysiology of mood and anxiety disorders, and in the processing of affective stimuli (Deakin, 1991; Graeff *et al*, 1986). More specifically, central 5-HT has long been thought to have a critical role in the adaptation of the animals to aversive events (Deakin and Graeff, 1991) and, more recently, to mediate a negative prediction error signal for future threat and punishment (Cools *et al*, 2008a; Daw *et al*, 2002). Accordingly, the majority of studies on

cognitive and affective processing in depressed patients highlight strong biases towards negative stimuli and away from positive ones, which interfere with normal cognitive functioning (Elliott *et al*, 1997; Elliott *et al*, 1996; Gotlib *et al*, 2004; Murphy *et al*, 2003; Roiser *et al*, 2009; Siegle *et al*, 2001), while long-term treatment with selective serotonin reuptake inhibitors (SSRIs) counteracts these biases. Moreover, lowering brain content of 5-HT by acute tryptophan depletion (ATD) in healthy subjects, causes similar biases in neuropsychological tasks assessing affective decision-making and punishment prediction (Cools *et al*, 2008b; Murphy *et al*, 2002; Rogers *et al*, 2003; Roiser *et al*, 2006). Additionally, in rats and other animals, 5-HT modulates the processing of aversive stimuli (Burghardt *et al*, 2004; Dayan and Huys, 2009; Inoue *et al*, 2004; Stutzmann and LeDoux, 1999; Wilkinson *et al*, 1995).

An effective way of measuring an individual's reaction to positive and negative feedback is to assess lose-shift and win-stay behavior in a two-choice probabilistic decision-making task (Paulus *et al*, 2002; Paulus *et al*, 2003). In the present study, we used an operant version of the probabilistic reversal learning task (PRL, Lawrence *et al*, 1999; Swainson *et al*, 2000) adapted for the first time for use in rats. The PRL task is widely adopted in clinical settings and has been proven highly sensitive in detecting cognitive deficits in a wide array of pathological states such as schizophrenia (Waltz and Gold, 2007), Parkinson's disease (Cools *et al*, 2001; Peterson *et al*, 2009; Swainson *et al*, 2000), bipolar (Roiser *et al*, 2009) and depressive (Murphy *et al*, 2003; Taylor Tavares *et al*, 2008) disorders.

With this paradigm it is possible to estimate the conditional probability of switching a response upon receiving spurious negative feedback (i.e., lack of reward) and that of maintaining a ‘response set’ that is rewarded on a high proportion of trials. The probabilistic nature of this task enhances the occurrence of error processing, thus making it particularly suitable for detecting changes in reward and negative feedback sensitivity.

Manipulating brain 5-HT levels by acute administration of the SSRI citalopram has been shown to cause deficits in acquiring a PRL task and increased negative feedback sensitivity in healthy volunteers (Chamberlain *et al*, 2006). Enhanced impact of failure on subsequent performance can also be observed in depressed patients during the execution of the PRL task (Murphy *et al*, 2003). However, these results are in apparent contrast with the widespread use of SSRIs in depressed patients and with recent findings on the beneficial effect of the potent SSRI escitalopram in a PRL paradigm in rats (Brown *et al*, 2008). Thus, it is not clear whether SSRI administration improves or impairs behavioural flexibility and whether depressed patients, that are oversensitive to negative feedback – and hyposensitive to positive feedback (e.g., Henriques *et al*, 1994) – would benefit from SSRIs treatment also on this aspect of their pathology.

In order to better understand the role of 5-HT on cognitive processes affected by performance feedback, we tested the effects of various manipulations of the 5-HT system on the sensitivity of rats to negative and positive feedback with the PRL task. We administered three doses of the SSRI citalopram in experiment 1 and tested the effects of repeated and subchronic administration of the same drug in the second experiment. Then,

we challenged the same animals with a low dose of citalopram, which is known to further increase 5-HT levels in prefrontal areas of sub-chronically treated animals (Invernizzi *et al*, 1994; Muraki *et al*, 2008). In experiment 3 we assessed animals' performance after global depletion of brain 5-HT. We anticipated that lowering brain 5-HT content would lead to increased lose-shift behaviour, according to published literature and recent theorizing (Cools *et al*, 2008a). Boosting 5-HT neurotransmission, instead, would decrease the impact of negative feedback on subsequent performance increasing the number of reversals completed by the animals.

Materials and methods

Subjects

Animals used in this study were male adult Lister hooded rats (Charles River, UK). All subjects were housed in groups of four under a reversed 12:12 hr light-dark cycle (white lights off at 07:30), and were tested during the dark phase of this cycle. In all experiments rats were mildly food restricted to approximately 85% of their free feeding weights. This was achieved by providing 15-20 g of food per day (Purina laboratory chow). Food restriction started at least one week before the beginning of training. Water was freely available except during test sessions. All experiments were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1986 (PPL 80/2234).

Training procedure

Rats were trained in twelve 5-hole operant chambers (Med Associates, Georgia, VT) described in detail elsewhere (Bari *et al*, 2008) and controlled by the Whisker control

system (Cardinal and Aitken, 2001). The experimental procedures were implemented using custom software written in Visual Basic by ACM. After being habituated to the test environment with free reward pellets in the food magazine, rats were presented with only one hole illuminated per trial randomly assigned to a hole adjacent (immediately left or right) of the central aperture. A nose poke in the illuminated hole resulted in the delivery of a single food pellet (Noyes dustless pellets; Sandown Scientific, Middlesex, UK) in the food magazine situated on the opposite wall of the chamber. Retrieval of the pellet from the magazine immediately initiated the next trial. A nose poke in any non-illuminated hole resulted in a 5-s time out. Performance was considered to have stabilized when accuracy levels were at least 90% over two consecutive sessions. Animals that showed a side bias were excluded from the study. This was defined by choice behavior greater than 55 % on one of the two holes (i.e., more than 5 % of errors made on the same hole).

When subjects reached stable levels of accuracy they were presented with two simultaneously illuminated apertures on either side of the central aperture. Reinforcement contingencies were modified so that one hole was the 'correct' location giving food pellets on 80% of trials, and the other was the 'incorrect' location which resulted in reinforcement on 20% of trials when chosen. On non-rewarded trials the animal received a 2.5-s time out. The light stimuli were presented for 30 seconds and, if there was no response within this time period, the trial was deemed an omission which triggered a 5-s timeout. A response made in one of the unlit holes was without any programmed consequence. If a subject chose the 'correct' hole on eight consecutive occasions, the contingencies were reversed such that the 'correct' hole became the 'incorrect' hole and

the previously ‘incorrect’ hole became the ‘correct’ hole. Animals were given one session per day, each consisting of 200 trials to be completed within 40 minutes.

Experiment 1: Acute citalopram administration

Twelve Lister hooded rats were initially trained as described above. One rat was excluded for side bias. After five drug-free sessions performance was stable and drug testing started. Animals were divided into 4 groups matched for performance accuracy and injected intraperitoneally (i.p.) with vehicle or citalopram hydrobromide (1, 5, 10 mg/kg; Tocris, Bristol, UK) according to a fully randomized Latin square design. Citalopram was dissolved in 0.01 M phosphate buffer saline (PBS) and administered 30 minutes before the test session.

Experiment 2: Repeated and subchronic citalopram administration

Eighteen rats were trained on the PRL task. After excluding side-biased animals fourteen rats were divided into two groups matched for baseline performance. The citalopram group (‘Cit’) received 5 mg/kg of citalopram 30 minutes before testing for 7 consecutive days, while the vehicle group (‘Veh’) received the same number of daily injections of 0.01 M PBS. This dose of citalopram was chosen because it did not influence performance when administered acutely in experiment 1.

After 7 days the Cit group received 10 mg/kg of citalopram twice a day (i.b.d., at least ~8 hours apart and ~4 hours before the test sessions) for 5 consecutive days. We reasoned that this regimen of drug administration would allow to separate the effects caused by repeated citalopram administration shortly before testing from long-lasting effects of

subchronic dosing. The Veh group received the same treatment regimen, but of PBS injections. On the thirteenth day, all animals received an injection of 3 mg/kg of citalopram 30 minutes before the start of the test session.

Experiment 3: Forebrain 5-HT depletion

Eighteen rats went through the initial training and baseline sessions as in experiment 1 and none of them displayed side bias. They were divided into 2 groups matched for baseline performance, pre-treated with 20 mg/kg of desipramine HCl (i.p., Sigma, UK) to protect noradrenergic neurons and, after 30 minutes, anesthetized with 100 ml/kg Avertin (10 g of 2,2,2-tribromoethanol (Sigma, Poole, UK) in 5 g of tertiary amyl alcohol, diluted in a solution of 40 ml of ethanol and 450 ml of PBS). They were subsequently secured in a stereotaxic frame with the incisor bar set at -3.3 mm relative to the interaural line. Two holes were drilled in the skull and bilateral intracerebroventricular (i.c.v.) infusions were made through stainless steel cannulae at the following stereotaxic coordinates: AP -0.9 mm from bregma, L \pm 1.5 mm from the midline and DV -3.5 mm from dura. Nine rats received bilateral infusions of 80 μ g 5,7-dihydroxytryptamine (5,7-DHT) creatinine sulfate diluted in 10 μ l 10% ascorbic acid in saline and control rats (n=9) received 10 μ l of vehicle. After each infusion injectors were left in place for 2 mins before withdrawal.

Rats were left undisturbed for 10 days allowing complete recovery from surgery and degeneration of 5-HT neurons (Bjorklund *et al*, 1975) before being re-trained. At the end of the experiments rats were sacrificed by CO₂ asphyxiation and their brains removed quickly and rapidly frozen on dry ice. Bilateral aliquots of tissue (0.4-2 mg) were subsequently obtained from coronal sections (150 μ m thickness) using a stainless steel

micro-punch (0.75 mm diameter) from the following brain regions: prelimbic cortex (PrL), anterior cingulate cortex (ACC), orbitofrontal cortex (OFC), nucleus accumbens (NAC), dorsomedial striatum (DMS), dorsolateral striatum (DLS), amygdala (Amg) and hippocampus (HPC).

Aliquots were weighed and then homogenized in 100 μ l 0.2 M perchloric acid. Samples were centrifuged at 6000 rpm for 20 mins at 4°C and the supernatant was analyzed for DA, dihydroxyphenylacetic acid (DOPAC), noradrenaline (NA), 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) content by reversed-phase, high-performance liquid chromatography (HPLC), as described previously (Matthews *et al*, 2001).

Main measures and statistical analysis

Data Analysis

Data were compiled in a relational database (Microsoft Access 2002) and analysed using SPSS 12.0.1 (SPSS, Chicago, IL, USA). Win-stay/lose-shift behaviour, reversals completed, latency data (to respond to the stimuli and to collect food pellets) and total number of ‘incorrect’ choices and pellets earned were subjected to repeated-measures analyses of variance (ANOVA), with “dose” (four levels: Veh, Cit 1, Cit 5, Cit 10) as within-subject factor in experiment 1, and with “group” (two levels: sham and lesion or Cit and Veh) as between-subject factor and “session” as within-subject factor in experiments 2 and 3. Neurochemical data were analyzed by independent samples t-test (two-tailed). All tests of significance were performed at $\alpha = 0.05$. Homogeneity of variance was verified using Levene’s test. For repeated-measured analyses, the Mauchly’s test of sphericity was applied and the degrees of freedom corrected to more

conservative values using the Huynh-Feldt epsilon ϵ whenever the sphericity assumption was violated. Corrected degrees of freedom are presented rounded to the nearest integer. For pair-wise comparisons, values were adjusted using Sidak's correction factor for multiple comparisons (Howell, 1997).

Animals' choices during the task were analyzed according to the outcome of each preceding trial (reward or punishment) and expressed as a ratio. The proportion of win-stay (i.e., the number of times the animal received a reward and then chose the same hole as that chosen on the previous trial, divided by the total number of rewarded trials) and lose-shift (i.e., the number of times the animal changed its choice after having been punished on the previous trial, divided by the total number of punished trials) scores for the 'correct' hole only were analyzed separately. *Negative feedback sensitivity* (NFS) was defined as the likelihood that the subject will choose the 'incorrect' stimulus after a 'correct' choice followed by a misleading negative feedback (i.e., lose-shift). *Reward sensitivity*, instead, was defined as the overall likelihood that the subject does *not* shift away from a rewarded 'correct' choice (i.e., win-stay). Since in experiment 1 animals perform only one test session for each drug dose, win-stay/lose-shift ratios were analyzed separately for the acquisition phase and the first reversal phase in order to increase the sensitivity of the experimental design employed.

Results

Experiment 1: Effects of acute citalopram administration

Citalopram affected the total number of reversals achieved (Fig.1a; $F(3,22) = 9.973$, $p < .001$). While the lowest dose (1 mg/kg) decreased the number of reversals ($p < .005$),

the highest dose (10 mg/kg) increased the number of reversals completed ($p < .05$) as compared to vehicle-treated animals (Figure 1a). No significant differences were found between the vehicle control group and the intermediate dose group (5 mg/kg). Citalopram treatment did not influence win-stay performance, although there was a significant effect on lose-shift behavior during the reversal phase (Figure 1d; $F(3,30) = 11.520$, $p < .001$). Pairwise comparisons showed that after 1 mg/kg of citalopram, lose-shift was significantly higher than vehicle ($p < .05$), whereas after 10 mg/kg it was significantly lower ($p < .05$). There was no significant effect of treatments on latencies, number of pellets earned and total number of 'incorrect' choices.

In summary, acute citalopram administration exerted opposing effects on PRL performance depending on the dose: a high dose increased the number of reversals completed and decreased the probability of shifting after receiving negative feedback, while a low dose caused the animals to complete fewer reversals and made them more likely to shift after receiving spurious negative feedback.

Experiment 2: Effects of repeated (5 mg/kg/day) and subchronic (10 mg/kg, i.b.d.) administration of citalopram

Before undergoing drug administration, two groups of animals matched for number of reversals achieved over the last 3 sessions were formed (7 animals in the group Veh and 7 animals in the group Cit). In the first part of the experiment (5 mg/kg of citalopram daily, 30 minutes before sessions), there was no effect of the repeated treatment on the number of reversals completed over 7 sessions. However, there was a significant difference between the two groups on win-stay behavior ($F(1,12) = 6.454$, $p < .05$) with the Cit group

displaying higher reward sensitivity (Figure 2b). Lose-shift behavior (Figure 2c) was not different between the two groups ($F(1,12) = 1.395$, ns) during this part of the experiment, but there was a significant session by group interaction ($F(6,72) = 2.398$, $p < .05$).

In the second part of the experiment (10 mg/kg, i.b.d.) repeated measure ANOVA detected a significant increase in the number of reversals completed (Figure 2a) by the Cit group ($F(1,12) = 5.581$, $p < .05$), but no significant effects on any other variable.

In the third part of the experiment (Figure 3a), administration of a single dose of citalopram (3 mg/kg), 30 minutes before testing started to both groups, caused a significant increase in the number of reversals completed by the animals of the Cit group ($F(1,12) = 5.444$, $p < .05$). There was also a significant difference on win-stay behavior between the two groups ($F(1,12) = 7.992$, $p < .05$), with the Cit group showing higher levels of win-stay behavior after a single citalopram challenge and no significant difference between the two groups on lose-shift behavior ($F(1,12) = .125$, ns) (Figure 3b). Moreover, the acute challenge of citalopram caused the rats in the Cit group to respond faster to the stimuli compared to the rats in the Veh group ($F(1,12) = 5.946$, $p < .05$). There were no other significant effects of treatments on reaction times, total pellets earned and total number of 'incorrect' choices.

In sum, repeated (once a day, 5 mg/kg) citalopram administration just before the beginning of the test session increased win-stay, but did not influence other variables while subchronic dosing of the same compound (10 mg/kg, i.b.d.) increased the number of reversals completed by the animals (Figure 2). An acute injection of citalopram (3 mg/kg) further increased the number of reversals achieved, as well as win-stay behavior,

but only in animals previously treated with the drug (Figure 3). Finally, this latter manipulation also speeded pretreated animals' reaction time.

Experiment 3: Effects of forebrain 5-HT depletion

Ex-vivo Neurochemistry

Consistent with previously published reports (Harrison *et al*, 1997; Winstanley *et al*, 2003, 2004), animals that received ICV 5,7-DHT infusions showed an almost total depletion of brain 5-HT and lower levels of the metabolite 5-HIAA in all the brain regions examined (Table 1; 5-HT: PrL, $t(14) = -2.17$; ACC, $t(7) = -2.87$; OFC, $t(7) = -2.75$; NAC, $t(8) = -2.48$; DMS, $t(14) = -2.42$; DLS, $t(7) = -2.48$; Amg, $t(7) = -2.49$; DHPC, $t(7) = -3.24$; all $p < .05$; two-tailed) and lower levels of the metabolite 5-HIAA in all the brain regions examined (5-HIAA, $t(14) = 5.64$, $p < .001$; two-tailed). Levels of DA (PrL, $t(14) = -.160$; ACC, $t(14) = -.091$; OFC, $t(14) = -.654$; NAC, $t(14) = -1.431$; DMS, $t(14) = .033$; DLS, $t(14) = -.144$; Amg, $t(14) = .742$; DHPC, $t(14) = -.220$; all n.s; two-tailed), NA (PrL, $t(14) = .056$; ACC, $t(14) = -.396$; OFC, $t(14) = -.306$; NAC, $t(14) = -.964$; DMS, $t(14) = .269$; DLS, $t(14) = .093$; Amg, $t(14) = -1.804$; DHPC, $t(10) = .755$; all n.s.; two-tailed) and DOPAC ($t(14) = 1.08$, ns; two-tailed) relative to controls.

Probabilistic reversal learning

A few days after surgery, one animal (sham group) died from postoperative complications. One animal from the lesion group was eliminated from the analysis as it had incomplete 5-HT depletion. None of the remaining animals displayed significant side biases. The final numbers were 8 shams and 8 lesioned rats. Data were analyzed over 7

consecutive sessions starting from the second day on task after surgery. Repeated measures ANOVA of win-stay performance revealed a significant main effect of session ($F(5,65) = 4.869, p < .005$) and group ($F(1,14) = 5.606, p < .05$) (Figure 4a) with lesioned animals displaying less win-stay behavior as compared to controls. Analysis of lose-shift behavior (Figure 4b) showed a main effect of session ($F(5,68) = 3.686, p < .005$). The effect of group on lose-shift was close to significance ($F(1,14) = 4.13, p = .062$), but there was no interaction between session and group ($F(5,68) = 1.291, ns$). However, since we expected an effect of the lesion on the lose-shift metric, we limited the analysis to the first four sessions. In this case the ANOVA revealed a significant increase in lose-shift behaviour for the lesion group ($F(1,14) = 5.544, p < .05$), revealing the transient nature of the effect.

The total number of reversals achieved by the animals (Figure 4c) increased over sessions ($F(4,52) = 4.251, p < .01$), but no interaction was found with the variable group ($F(4,52) = 1.372, ns$). There was a significant effect of group in the number of reversals completed ($F(1,14) = 15.774, p < .001$), with lesioned animals completing fewer reversals ($p < .001$). Depleted animals were also faster to respond to the illuminated apertures ($F(1,14) = 13.267, p < .001$), but no difference was found in the latency to collect the reward from the food magazine, in the total amount of food pellets earned and in the number of ‘incorrect’ choices.

See table 2 for a summary of the effects of the different experimental manipulations.

Discussion

Our results show, apparently for the first time, how different manipulations of 5-HT neurotransmission in rats result in altered sensitivity to positive and negative feedback in the setting of a probabilistic reversal learning (PRL) task, analogous to that used in humans. Acute administration of a low dose of the SSRI citalopram (1 mg/kg), which decreases 5-HT system activity (see below), impaired subjects' performance as expected, reducing the number of reversals completed. This effect was paralleled by an increase in lose-shift behavior (i.e., higher negative feedback sensitivity) – a result also observed in healthy human volunteers following acute citalopram administration (Chamberlain *et al*, 2006). By contrast, acute administration of a higher dose of citalopram (10 mg/kg) improved rats' performance on the PRL task, consistent with a recent study using 1 mg/kg escitalopram (the S-enantiomer of citalopram) on a maze version of the same task (Brown *et al*, 2008). Escitalopram is much more potent than the racemic compound citalopram in increasing extracellular 5-HT levels (Mork *et al*, 2003) and displays a faster onset of antidepressant action in both patients (Gorman *et al*, 2002) and animal models of depression (Sanchez *et al*, 2003).

Our results also demonstrate that depleting 5-HT from the rat forebrain unexpectedly modulated the impact of *positive* (and, only transiently, of negative) feedback on subsequent performance, making the rat more likely to switch away from a rewarded choice (i.e., decreased win-stay). This result thus mirrors that obtained after increasing tonic levels of extra-synaptic 5-HT by repeated injections of citalopram (experiment 2). This latter manipulation resulted in the animals being more sensitive to reward (increased win-stay) and to perform better in the task.

Thus, in general, increasing 5-HT function, either by acute administration of a high dose of citalopram or by sub-chronic treatment with the same drug, caused an improvement in the performance of the animals, as characterized by a higher number of reversals completed. By contrast, reducing forebrain 5-HT activity by chronic depletion or by an acute low dose of citalopram impaired reversal performance. However, these effects were associated with different behavioral outcomes (in terms of win-stay/lose-shift behavior), depending on the specific experimental manipulation.

In experiment 1, we found contrasting effects of acute administration of a low compared to a high dose of citalopram. Various studies have shown that single administrations of clinically relevant doses of SSRIs cause a marked increase of extracellular 5-HT in midbrain raphé nuclei, but not in the prefrontal cortex (PFC) region (Bel and Artigas, 1992; Gartside *et al*, 1995; Invernizzi *et al*, 1992; Malagie *et al*, 1996). More relevant for the present study, Invernizzi and colleagues (1992) showed that 5-HT levels, as measured by *in vivo* microdialysis, are increased in the PFC of freely moving rats after 10 (but not 1) mg/kg of citalopram administered intraperitoneally. This pattern of findings is consistent with electrophysiological studies in animals showing that a single challenge with a low dose of an SSRI temporarily inhibits the firing of 5-HT neurons due to inhibitory autoreceptor activation in the raphé nuclei (Artigas *et al*, 1996; Hajos *et al*, 1995). Low doses of SSRIs increase 5-HT levels to a level that floods somatodendritic 5-HT_{1a} autoreceptors, causing inhibition of 5-HT neuronal discharge (Aghajanian, 1987), synthesis (Barton and Hutson, 1999; Carlsson and Lindqvist, 1978) and release (Adell

and Artigas, 1991; Hjorth and Auerbach, 1994). Higher doses hypothetically bypass this inhibitory mechanism, allowing for a net increase in prefrontal 5-HT extracellular content (Bymaster *et al*, 2002; Invernizzi *et al*, 1992; Koch *et al*, 2002; Pozzi *et al*, 1999). Moreover, biphasic dose-response curves have been observed after citalopram administration in a variety of tests (Dekeyne *et al*, 2000; Hashimoto *et al*, 2009; Sanchez and Meier, 1997). The exact mechanisms underlying the opposite effects of different doses of citalopram in the PRL task, however, remain unclear. We cannot exclude, for example, that they are due to the recruitment of different receptor sub-types with varying affinity for the ligand or to the involvement of neurotransmitter systems other than 5-HT.

The results of experiment 1 show that increasing 5-HT transmission by a high dose of citalopram promotes behavioural flexibility and provides resilience to negative uncontrollable events (i.e., decreased lose-shift behavior) probably through a forebrain 5-HT_{1a}-dependent mechanism (Deakin *et al*, 1991). Conversely, a low dose elicits the opposite effect, increasing the impact of negative feedback on the subsequent choice, presumably via temporary silencing of 5-HT system activity through stimulation of 5-HT_{1a} autoreceptors in the raphé nuclei (Sharp *et al*, 1989; Sprouse and Aghajanian, 1987). This latter effect would hypothetically increase the impact of phasic signalling on 5-HT_{2/1c} receptors mediating the avoidance reaction to negative feedback, consistent with the formulation of Deakin and Graeff (1991).

Regardless of the direction of the effects elicited by different doses of citalopram after acute administration, only lose-shift (and not win-stay) behavior was affected by these

treatments. This concurs with some studies in humans subjects that found *acute* 5-HT manipulations selectively to affect reactions to negative stimuli (Browning *et al*, 2007; Chamberlain *et al*, 2006), punishment prediction (Cools *et al*, 2008b) and the activation of brain areas involved in error detection and processing of aversive events (Anderson *et al*, 2007; Del-Ben *et al*, 2005; Evers *et al*, 2005; McKie *et al*, 2005).

We also found that repeated administration of citalopram (5 mg/kg daily, 30 minutes before test sessions) enhanced win-stay behavior in rats performing the PRL task. Furthermore, enhancing 5-HT neurotransmission by sub-chronic citalopram administration (10 mg/kg, i.b.d.), increased the number of reversals completed and a subsequent challenge with a low dose of the drug (3 mg/kg), administered 30 minutes before the test session, augmented both the number of reversals completed and win-stay behavior, but only in animals pre-treated sub-chronically with citalopram. These results show that elevating 5-HT tone causes large improvements in performance and a selective increase in win-stay behavior, similarly to the beneficial effects of boosting 5-HT neurotransmission by repeated SSRI administration in depressive patients. Citalopram-treated animals showed heightened reward sensitivity and returned to choose the option that had been rewarded on the immediately preceding trial more often than controls. This latter effect probably requires the drug to be present at the time of testing, because it disappeared when citalopram (10mg/kg/i.b.d.) was administered few hours before and after testing sessions.

An effect opposite to the one caused by repeated citalopram administration resulted from 5-HT depletion via icv 5,7-DHT infusion. 5-HT depleted animals achieved fewer reversals than sham-operated rats, displayed an earlier increase in lose-shift behavior (a difference disappearing over sessions) and a long lasting decrease in win-stay behavior. Depleted animals were also faster to respond to the apertures, an effect that has been already observed after the same lesion technique (Harrison *et al*, 1997; Winstanley *et al*, 2004). However, there was no difference in the latency to collect the reward between the two groups, which is a sensitive measure of motivation for food (Carli and Samanin, 1992; Harrison *et al*, 1997) and, together with the decrease in reward sensitivity (i.e., lower win-stay), largely excludes a motivational explanation of the increased speed in lesioned animals.

Thus, in the context of the PRL task, long-term enhancement of 5-HT neurotransmission, in addition to improving behavioral flexibility, selectively increases reward sensitivity, while chronic 5-HT depletion produces the opposite effect, making the animals less sensitive to positive feedback. The transient nature of the increase in lose-shift behaviour after 5-HT depletion might have been a consequence of functional adaptations and/or recovery in the brain of lesioned animals or, less likely, of incomplete degeneration of 5-HT-containing neurons during the first part of the experiment (see Baumgarten *et al*, 1974).

From a neurobiological perspective, the effects observed after acute, as distinct from long-term, 5-HT manipulations, could be ascribed to the contribution of 5-HT receptors

that down-regulate after repeated SSRI treatment. From a theoretical point of view, a possible explanation is suggested by computational theories of the role of tonic fluctuations in 5-HT brain levels in reporting a long-term average reward prediction signal and of phasic 5-HT signals in negative prediction error as opposed to the role of the dopaminergic system (Daw *et al*, 2002).

Implications for the hypothetical role of 5-HT in punishment prediction

Serotonergic neurotransmission has long been hypothesized to have an important role in the control of an aversive motivational system (Deakin, 1983; Deakin *et al*, 1991) and in the pathophysiology of depressive states (Delgado *et al*, 1990; Shopsin *et al*, 1976). Whilst DA has been associated with the expression of an appetitive reward system (Schultz *et al*, 1997), it is plausible that it works in mutual opponency with a system which signals the prediction of punishment instead of reward (Daw *et al*, 2002; Deakin *et al*, 1991).

As pointed out in a recent review (Cools *et al*, 2008a), the role of 5-HT in the anticipation of punishment seems in contradiction with the observations that decreased brain 5-HT levels – by experimental manipulations or as a consequence of hypothesized reductions in psychiatric disorders such as depression – actually *enhance* the impact of negative feedback on subsequent performance. However, lower extracellular levels of tonic neurotransmission might theoretically increase ‘signal-to-noise ratios’ when the serotonergic neurons fire to signal the prediction of punishment, similarly to the mechanism of action of DA in signaling reward receipt or its anticipation (Frank *et al*, 2004; Grace, 1991; Schultz *et al*, 2000). The opposite would be true with higher tonic

levels of 5-HT, which are predicted to dampen the impact of this signal (Cools *et al*, 2008a). This framework is consistent, at least in some aspects, with recent findings in humans and with the results presented here. Indeed, decreasing the activity of 5-HT system by acute administration of low doses of SSRI in humans (Chamberlain *et al*, 2006) and in rats (this report), has similar effects to that caused by ATD (Evers *et al*, 2005), namely increasing the impact of negative feedback. This mechanism is also potentially able to explain the exaggerated reaction to punishment in depressed patients (Elliott *et al*, 1997; Murphy *et al*, 2003).

In the present report, depleting 5-HT brain content caused only a transient increase in lose-shift. This is probably because, following such a profound manipulation, 5-HT neurons are not able to send reliable punishment signals as a consequence of the almost complete depletion of the neurotransmitter and/or 5-HT fiber degeneration, which happens gradually after the toxin has been infused (Baumgarten *et al*, 1974). However, in the first part of the experiment (Fig 4b), the increase in lose-shift behaviour is strikingly similar to the impairment observed in depressed patients (i.e., increased loose-shift). The effect of the repeated citalopram treatment is consistent with the recovery of depressive symptoms after prolonged SSRIs treatment, but, argues against the framework previously described for the role of 5-HT in signaling punishment. In our case, we would have expected that elevating tonic levels of 5-HT would dampen the punishment signal, leading to an effect similar to an acute high dose of citalopram namely, to decrease lose-shift behaviour. We did not observe such effects, probably because of more complex interactions and adaptations within and outside the 5-HT system.

The increase in win-stay behavior caused by repeated citalopram administration could be a consequence of alterations in the coupling of the 5-HT system with dopamine, which is more related to reward sensitivity (Nestler and Carlezon, 2006). In fact, repeated SSRI administration is known to modulate the firing rate of mesocorticolimbic DA neurons (Bortolozzi *et al*, 2005; Di Mascio *et al*, 1998; Dremencov *et al*, 2009; Sekine *et al*, 2007) through long-term adaptations of 5-HT₂ receptors (Blackburn *et al*, 2006; Esposito, 2006; Pehek *et al*, 2006). However, more experiments are needed to define the precise role of 5-HT/DA interactions in the sensitivity to positive and negative feedback.

Summary

The results show that the beneficial effects of SSRIs on executive function depend on the exact dose and dosing regimen used. Increasing and decreasing central 5-HT levels exert opposite effects on reward and negative feedback sensitivity, resembling the effects of manipulation of 5-HT levels in healthy and depressed subjects on similar tasks. However, it was observed for the first time in rats that acute manipulations of the 5-HT system affect principally negative feedback sensitivity, while long lasting treatments significantly modulate reward (positive feedback) sensitivity in the PRL task.

Disclosure

TWR discloses consultancy for Cambridge Cognition, Pfizer, Eli Lilly Inc., GlaxoSmithKline, Pangenics, Allon Therapeutics and Roche. TWR also discloses the receipt of grants from Pfizer and GlaxoSmithKline and editorship for Springer Verlag (Psychopharmacology). AB, DET, DC, ACM, AA-M and JWD, have nothing to disclose.

Acknowledgements

This research was supported by a Wellcome Trust programme grant (076274/z/04/z) and completed within the Cambridge University Behavioral and Clinical Neuroscience Institute, supported by a joint award from the Medical Research Council (MRC) and Wellcome Trust. AB was supported by an MRC studentship. The authors would like to thank Dr David Belin for help with data analysis.

References

- Adell A, Artigas F (1991). Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. *Naunyn-Schmiedeberg's archives of pharmacology* **343**(3): 237-244.
- Aghajanian GK, Sprouse JS, Rasmussen K. (1987). Physiology of midbrain serotonin system. In: HY M (ed). *Psychopharmacology: The third generation of progress*. Raven Press: New York, pp 141-149.
- Anderson IM, Del-Ben CM, McKie S, Richardson P, Williams SR, Elliott R, *et al* (2007). Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. *Neuroreport* **18**(13): 1351-1355.
- Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT_{1A} antagonists. *Trends in neurosciences* **19**(9): 378-383.
- Bari A, Dalley JW, Robbins TW (2008). The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. *Nature protocols* **3**(5): 759-767.
- Barton CL, Hutson PH (1999). Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT_{1A} and 5-HT_{1B/D} autoreceptors. *Synapse (New York, NY)* **31**(1): 13-19.
- Baumgarten HG, Bjorklund A, Lachenmayer L, Rensch A, Rosengren E (1974). De- and regeneration of the bulbospinal serotonin neurons in the rat following 5,6- or 5,7-dihydroxytryptamine treatment. *Cell Tissue Res* **152**(3): 271-281.
- Beats BC, Sahakian BJ, Levy R (1996). Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. *Psychological medicine* **26**(3): 591-603.
- Bel N, Artigas F (1992). Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. *European journal of pharmacology* **229**(1): 101-103.
- Bjorklund A, Baumgarten HG, Rensch A (1975). 5,7-Dihydroxytryptamine: improvement of its selectivity for serotonin neurons in the CNS by pretreatment with desipramine. *Journal of neurochemistry* **24**(4): 833-835.
- Blackburn TP, Suzuki K, Ashby CR, Jr. (2006). The acute and chronic administration of the 5-HT_{2B/2C} receptor antagonist SB-200646A significantly alters the activity of

spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. *Synapse (New York, NY)* **59**(8): 502-512.

Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F (2005). The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. *Journal of neurochemistry* **95**(6): 1597-1607.

Brown HD, Osisoma S, Sweeney JA, Ragozzino ME (2008) The selective serotonin reuptake inhibitor, escitalopram, enhances probabilistic reversal learning in rats. In *SFN abstract*, Washington DC.

Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ (2007). A single dose of citalopram increases fear recognition in healthy subjects. *Journal of psychopharmacology (Oxford, England)* **21**(7): 684-690.

Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004). The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. *Biological psychiatry* **55**(12): 1171-1178.

Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, *et al* (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. *Psychopharmacology* **160**(4): 353-361.

Cardinal RN, Aitken MRF (2001) Whisker, version 2.2, computer software.

Carli M, Samanin R (1992). Serotonin₂ receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. *Psychopharmacology* **106**(2): 228-234.

Carlsson A, Lindqvist M (1978). Effects of antidepressant agents on the synthesis of brain monoamines. *J Neural Transm* **43**(2): 73-91.

Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. *Science (New York, NY)* **311**(5762): 861-863.

Cools R, Barker RA, Sahakian BJ, Robbins TW (2001). Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. *Cereb Cortex* **11**(12): 1136-1143.

Cools R, Roberts AC, Robbins TW (2008a). Serotonergic regulation of emotional and behavioural control processes. *Trends in cognitive sciences* **12**(1): 31-40.

Cools R, Robinson OJ, Sahakian B (2008b). Acute tryptophan depletion in healthy volunteers enhances punishment prediction but does not affect reward prediction. *Neuropsychopharmacology* **33**(9): 2291-2299.

Daw ND, Kakade S, Dayan P (2002). Opponent interactions between serotonin and dopamine. *Neural Netw* **15**(4-6): 603-616.

Dayan P, Huys QJ (2009). Serotonin in affective control. *Annual review of neuroscience* **32**: 95-126.

Deakin JF (1991). Depression and 5HT. *International clinical psychopharmacology* **6 Suppl 3**: 23-28; discussion 29-31.

Deakin JFW (1983). Roles of brain serotonergic neurons in escape, avoidance and other behaviours. *Journal of Psychopharmacology* **43**: 563-577.

Deakin JFW, Graeff FG (1991). 5-HT and mechanisms of defence. *Journal of Psychopharmacology* **5**: 305-316.

Dekeyne A, Denorme B, Monneyron S, Millan MJ (2000). Citalopram reduces social interaction in rats by activation of serotonin (5-HT)_{2C} receptors. *Neuropharmacology* **39**(6): 1114-1117.

Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, *et al* (2005). The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. *Neuropsychopharmacology* **30**(9): 1724-1734.

Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990). Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. *Arch Gen Psychiatry* **47**(5): 411-418.

Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, Esposito E (1998). Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. *Brain research bulletin* **46**(6): 547-554.

Dremencov E, El Mansari M, Blier P (2009). Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. *J Psychiatry Neurosci* **34**(3): 223-229.

Elliott R, Dolan RJ, Frith CD (2000). Dissociable functions in the medial and lateral orbitofrontal cortex: evidence from human neuroimaging studies. *Cereb Cortex* **10**(3): 308-317.

Elliott R, Sahakian BJ, Herrod JJ, Robbins TW, Paykel ES (1997). Abnormal response to negative feedback in unipolar depression: evidence for a diagnosis specific impairment. *Journal of neurology, neurosurgery, and psychiatry* **63**(1): 74-82.

Elliott R, Sahakian BJ, McKay AP, Herrod JJ, Robbins TW, Paykel ES (1996). Neuropsychological impairments in unipolar depression: the influence of perceived failure on subsequent performance. *Psychological medicine* **26**(5): 975-989.

Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. *Current drug targets* **7**(2): 177-185.

Evers EA, Cools R, Clark L, van der Veen FM, Jolles J, Sahakian BJ, *et al* (2005). Serotonergic modulation of prefrontal cortex during negative feedback in probabilistic reversal learning. *Neuropsychopharmacology* **30**(6): 1138-1147.

Frank MJ, Seeberger LC, O'Reilly R C (2004). By carrot or by stick: cognitive reinforcement learning in parkinsonism. *Science (New York, NY)* **306**(5703): 1940-1943.

Gartside SE, Umbers V, Hajos M, Sharp T (1995). Interaction between a selective 5-HT_{1A} receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. *British journal of pharmacology* **115**(6): 1064-1070.

Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. *CNS spectrums* **7**(4 Suppl 1): 40-44.

Gotlib IH, Krasnoperova E, Yue DN, Joormann J (2004). Attentional biases for negative interpersonal stimuli in clinical depression. *Journal of abnormal psychology* **113**(1): 121-135.

Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. *Neuroscience* **41**(1): 1-24.

Graeff FG, Brandao ML, Audi EA, Schutz MT (1986). Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. *Behavioural brain research* **22**(2): 173-180.

Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996). Role of 5-HT in stress, anxiety, and depression. *Pharmacology, biochemistry, and behavior* **54**(1): 129-141.

Hajos M, Gartside SE, Sharp T (1995). Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. *Naunyn-Schmiedeberg's archives of pharmacology* **351**(6): 624-629.

Harrison AA, Everitt BJ, Robbins TW (1997). Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. *Psychopharmacology* **133**(4): 329-342.

Hashimoto S, Inoue T, Muraki I, Koyama T (2009). Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. *Progress in neuro-psychopharmacology & biological psychiatry* **33**(1): 113-117.

Henriques JB, Glowacki JM, Davidson RJ (1994). Reward fails to alter response bias in depression. *Journal of abnormal psychology* **103**(3): 460-466.

Hjorth S, Auerbach SB (1994). Further evidence for the importance of 5-HT_{1A} autoreceptors in the action of selective serotonin reuptake inhibitors. *European journal of pharmacology* **260**(2-3): 251-255.

Howell DC (1997). *Statistical methods for psychology*, 4th edition edn. Duxbury Press: Belmont, CA.

Hughes JR, Pleasants CN, Pickens RW (1985). Measurement of reinforcement in depression: a pilot study. *Journal of behavior therapy and experimental psychiatry* **16**(3): 231-236.

Inoue T, Li XB, Abekawa T, Kitaichi Y, Izumi T, Nakagawa S, *et al* (2004). Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. *European journal of pharmacology* **497**(3): 311-316.

Invernizzi R, Belli S, Samanin R (1992). Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. *Brain research* **584**(1-2): 322-324.

Invernizzi R, Bramante M, Samanin R (1994). Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT_{1A} receptors. *European journal of pharmacology* **260**(2-3): 243-246.

Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP (2002). R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an *in vivo* microdialysis and receptor binding study. *Neuropsychopharmacology* **27**(6): 949-959.

Lawrence AD, Sahakian BJ, Rogers RD, Hodge JR, Robbins TW (1999). Discrimination, reversal, and shift learning in Huntington's disease: mechanisms of impaired response selection. *Neuropsychologia* **37**(12): 1359-1374.

Malagie I, Trillat AC, Douvier E, Anmella MC, Dessalles MC, Jacquot C, *et al* (1996). Regional differences in the effect of the combined treatment of WAY 100635 and

fluoxetine: an in vivo microdialysis study. *Naunyn-Schmiedeberg's archives of pharmacology* **354**(6): 785-790.

Matthews K, Dalley JW, Matthews C, Tsai TH, Robbins TW (2001). Periodic maternal separation of neonatal rats produces region- and gender-specific effects on biogenic amine content in postmortem adult brain. *Synapse (New York, NY)* **40**(1): 1-10.

McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I, *et al* (2005). Neuronal effects of acute citalopram detected by pharmacMRI. *Psychopharmacology* **180**(4): 680-686.

Mork A, Kreilgaard M, Sanchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. *Neuropharmacology* **45**(2): 167-173.

Muraki I, Inoue T, Hashimoto S, Izumi T, Koyama T (2008). Effect of different challenge doses after repeated citalopram treatment on extracellular serotonin level in the medial prefrontal cortex: in vivo microdialysis study. *Psychiatry and clinical neurosciences* **62**(5): 568-574.

Murphy FC, Michael A, Robbins TW, Sahakian BJ (2003). Neuropsychological impairment in patients with major depressive disorder: the effects of feedback on task performance. *Psychological medicine* **33**(3): 455-467.

Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ (2002). The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. *Psychopharmacology* **163**(1): 42-53.

Nestler EJ, Carlezon WA, Jr. (2006). The mesolimbic dopamine reward circuit in depression. *Biological psychiatry* **59**(12): 1151-1159.

Paulus MP, Hozack N, Frank L, Brown GG (2002). Error rate and outcome predictability affect neural activation in prefrontal cortex and anterior cingulate during decision-making. *NeuroImage* **15**(4): 836-846.

Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA (2003). Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. *Biological psychiatry* **53**(1): 65-74.

Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS (2006). Evidence for the preferential involvement of 5-HT_{2A} serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. *Neuropsychopharmacology* **31**(2): 265-277.

Peterson DA, Elliott C, Song DD, Makeig S, Sejnowski TJ, Poizner H (2009). Probabilistic reversal learning is impaired in Parkinson's disease. *Neuroscience*.

Pozzi L, Invernizzi R, Garavaglia C, Samanin R (1999). Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. *Journal of neurochemistry* **73**(3): 1051-1057.

Robbins TW, Elliott R, Sahakian BJ (1996). Neuropsychology--dementia and affective disorders. *British medical bulletin* **52**(3): 627-643.

Rogers RD, Tunbridge EM, Bhagwagar Z, Drevets WC, Sahakian BJ, Carter CS (2003). Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. *Neuropsychopharmacology* **28**(1): 153-162.

Roiser JP, Blackwell AD, Cools R, Clark L, Rubinsztein DC, Robbins TW, *et al* (2006). Serotonin transporter polymorphism mediates vulnerability to loss of incentive motivation following acute tryptophan depletion. *Neuropsychopharmacology* **31**(10): 2264-2272.

Roiser JP, Cannon DM, Gandhi SK, Taylor Tavares J, Erickson K, Wood S, *et al* (2009). Hot and cold cognition in unmedicated depressed subjects with bipolar disorder. *Bipolar disorders* **11**(2): 178-189.

Sanchez C, Gruca P, Papp M (2003). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. *Behavioural pharmacology* **14**(5-6): 465-470.

Sanchez C, Meier E (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? *Psychopharmacology* **129**(3): 197-205.

Schultz W, Dayan P, Montague PR (1997). A neural substrate of prediction and reward. *Science (New York, NY)* **275**(5306): 1593-1599.

Schultz W, Tremblay L, Hollerman JR (2000). Reward processing in primate orbitofrontal cortex and basal ganglia. *Cereb Cortex* **10**(3): 272-284.

Sekine Y, Suzuki K, Ramachandran PV, Blackburn TP, Ashby CR, Jr. (2007). Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. *Synapse (New York, NY)* **61**(2): 72-77.

Sharp T, Bramwell SR, Grahame-Smith DG (1989). 5-HT₁ agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. *British journal of pharmacology* **96**(2): 283-290.

Shopsin B, Friedman E, Gershon S (1976). Parachlorophenylalanine reversal of tranlycypromine effects in depressed patients. *Arch Gen Psychiatry* **33**(7): 811-819.

Siegle GJ, Granholm E, Ingram RE, Matt GE (2001). Pupillary and reaction time measures of sustained processing of negative information in depression. *Biological psychiatry* **49**(7): 624-636.

Sprouse JS, Aghajanian GK (1987). Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HT_{1A} and 5-HT_{1B} agonists. *Synapse (New York, NY)* **1**(1): 3-9.

Steffens DC, Wagner HR, Levy RM, Horn KA, Krishnan KR (2001). Performance feedback deficit in geriatric depression. *Biological psychiatry* **50**(5): 358-363.

Stutzmann GE, LeDoux JE (1999). GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. *J Neurosci* **19**(11): RC8.

Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW (2000). Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. *Neuropsychologia* **38**(5): 596-612.

Taylor Tavares JV, Clark L, Furey ML, Williams GB, Sahakian BJ, Drevets WC (2008). Neural basis of abnormal response to negative feedback in unmedicated mood disorders. *NeuroImage* **42**(3): 1118-1126.

Waltz JA, Gold JM (2007). Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. *Schizophrenia research* **93**(1-3): 296-303.

Wilkinson LS, Humby T, Robbins TW, Everitt BJ (1995). Differential effects of forebrain 5-hydroxytryptamine depletions on Pavlovian aversive conditioning to discrete and contextual stimuli in the rat. *The European journal of neuroscience* **7**(10): 2042-2052.

Winstanley CA, Dalley JW, Theobald DE, Robbins TW (2003). Global 5-HT depletion attenuates the ability of amphetamine to decrease impulsive choice on a delay-discounting task in rats. *Psychopharmacology* **170**(3): 320-331.

Winstanley CA, Dalley JW, Theobald DE, Robbins TW (2004). Fractionating impulsivity: contrasting effects of central 5-HT depletion on different measures of impulsive behavior. *Neuropsychopharmacology* **29**(7): 1331-1343.

Table 1

Area	5-HT		DA		NA		
	% depletion	Sham	Lesion	Sham	Lesion	Sham	Lesion
PrL	90.8(6.5)	0.40(0.1)	0.02(0.01)*	1.75(1.3)	1.51(0.6)	1.01(0.1)	1.02(0.2)
ACC	96.8(2.4)	0.37(0.1)	0.01(0.009)*	0.77(0.4)	0.72(0.38)	1.12(0.1)	1.02(0.1)
OFC	100(0)	0.19(0.06)	0.00(0.00)*	2.45(1.4)	1.33(0.9)	0.91(0.3)	0.76(0.3)
NAC	86.8(13)	0.23(0.08)	0.02(0.02)*	5.55(2.1)	2.31(0.7)	1.4(0.2)	0.96(0.3)
DMS	95.7(4.2)	0.19(0.07)	0.005(0.005)*	9.76(4.1)	9.97(4.7)	0.94(0.3)	1.1(0.4)
DLS	86.6(10.1)	0.19(0.07)	0.01(0.007)*	9.26(4.8)	8.43(3.1)	2.04(0.6)	2.15(1.01)
Amg	100(0)	0.65(0.2)	0.00(0.00)*	2.99(0.9)	8.14(6.8)	2.3(0.7)	0.83(0.3)
HPC	99.5(0.49)	0.29(0.09)	0.001(0.001)*	0.31(0.1)	0.27(0.1)	2.1(0.6)	3.30(1.4)

* Significant difference ($p < 0.05$) between sham and lesion groups

ACC, anterior cingulate cortex; Amg, amygdala; DLS, dorsolateral striatum; DMS, dorsomedial striatum; HPC, hippocampus; NA, noradrenaline; NAC, nucleus accumbens; OFC, orbitofrontal cortex; PrL, prelimbic cortex.

The data are average levels (\pm SEM) expressed as picomoles per milligram.

Table 2

Manipulation	Dose	N of reversals	Lose-shift	Win-stay
Acute citalopram	1 mg/kg	↓	↑	—
	10 mg/kg	↑	↓	—
Repeated citalopram	5 mg/kg	—	—	↑
Subchronic citalopram (ibd)	10 mg/kg	↑	—	—
Acute challenge in subchronically treated rats	3 mg/kg	↑	—	↑
5-HT depletion	—	↓	↑*	↓

* Transient effect

Fig 1




Fig 2




Fig 3




Fig 4

